Synthesis and Development of Indole Based 5-HT3 Receptor Antagonists as Anti-Emetic Drugs in Oncology :An Update

被引：2

作者：

Rivera-Fonseca, Johana L. ^{[1
,2
]}

Gonzalez-Rivas, Nelly ^{[1
,2
]}

Basavanag Unnamatla, M., V ^{[1
,2
]}

Garcia-Eleno, Marco A. ^{[1
,2
]}

Reyes, Horacio ^{[3
]}

German Lopez-Valdez, L. ^{[4
]}

Corona-Becerril, David ^{[1
,2
]}

Cuevas-Yanez, Erick ^{[1
,2
]}

机构：

[1] UAEM UNAM, Ctr Conjunto Invest Quim Sustentable, Carretera Toluca Atlacomulco Km 14-5, Toluca 50200, Estado De Mexic, Mexico

[2] Univ Autonoma Estado Mexico, Fac Quim, Toluca 50120, Mexico

[3] Tecnol Estudios Super Jocotitlan, Div Ingn Quim, Carretera Toluca Atlacomulco Km 44-8, Jocotitlan, Edo, Mexico

[4] Univ Autonoma Chapingo, Dept Preparatoria Agr, Area Quim, Lab Prod Nat, Apartado 74,Km 38-5 Carretera Mexico Texcoco, Chapingo 56230, Mexico

来源：

CURRENT MEDICINAL CHEMISTRY | 2021年 / 28卷 / 42期

关键词：

Antiemetic drugs; 5-HT3; indole; synthesis; ondansetron; ramosetron; dolasetron; granisetron; ricaset-ron; tropisetron; CHEMOTHERAPY-INDUCED NAUSEA; IRRITABLE-BOWEL-SYNDROME; INDUCED EMESIS; 5-HYDROXYTRYPTAMINE(3) RECEPTORS; PHARMACOLOGICAL PROFILE; POSTOPERATIVE NAUSEA; ANTICIPATORY NAUSEA; THERAPEUTIC AGENT; CHRONIC TOXICITY; VOMITING CINV;

D O I：

10.2174/0929867328666210708091134

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

An important group of antiemetic drugs used in the treatment of nausea and vomiting after chemotherapy containing an indole moiety in their structures, working as 5hydroxytryptamine type 3 serotonin receptor antagonist (5-HT3). This study focuses on compounds bearing an indole core that present a 5-HT3 receptor antagonist activity, which have been successfully used as antiemetic drugs for reducing chemotherapy adverse secondary effects during cancer treatment. Their synthesis, biological activities, and some outstanding characteristics are discussed, providing a general outlook towards the development of more efficient antiemetic drugs.

引用

页码：8733 / 8754

页数：22

共 192 条

[1] 5-HT3-receptor antagonists in the management of nausea and vomiting in cancer and cancer treatment
Aapro, M
[J]. ONCOLOGY, 2005, 69 (02) : 97 - 109
[2] 5-Hydroxytryptamine type-3 receptor antagonists for chemotherapy-induced and radiotherapy-induced nausea and emesis - Can we safely reduce the dose of administered agents?
Aapro, M
Blower, P
[J]. CANCER, 2005, 104 (01) : 1 - 13
[3] Granisetron: An update on its clinical use in the management of nausea and vomiting
Aapro, M
[J]. ONCOLOGIST, 2004, 9 (06) : 673 - 686
[4] Aapro M., 2013, PREVENTION NAUSEA VO, DOI DOI 10.1007/978-1-907673-58-0
[5] Anticipatory nausea and vomiting
Aapro, MS
Molassiotis, A
Olver, I
[J]. SUPPORTIVE CARE IN CANCER, 2005, 13 (02) : 117 - 121
[6] SETRON - ARE 5-HT(3) RECEPTOR ANTAGONISTS DIFFERENT
AAPRO, MS
[J]. EUROPEAN JOURNAL OF CANCER, 1993, 29A (12) : 1655 - 1655
[7] Effects of 5-hydroxytryptamine (serotonin) type 3 antagoniosts on symptom relief and constipation in nonconstipated irritable bowel syndrome: A systematic review and meta-analysis of randomized controlled trials
Andresen, Viola
Montori, Victor M.
Keller, Jutta
West, Colin P.
Layer, Peter
Camilleri, Michael
[J]. CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2008, 6 (05) : 545 - 555
[8] Andrews P.L., 2016, MANAGEMENT CHEMOTHER, P5
[9] [Anonymous], 1996, CNS DRUG REV
[10] Anzeveno P.B., 1989, Eur. Patent, Patent No. [0 339 669, 0339669]

← 1 2 3 4 5 6 7 8 9 10 →